Hormone Management for Transgender Females

Introduction to Hormone Therapy

The American College of Physicians recommends a hormone management regimen for transgender females that includes transdermal 17β-estradiol (50-100 μg/24 hours) as first-line therapy, combined with an antiandrogen such as spironolactone to achieve testosterone levels <50 ng/dL 1

Transdermal 17β-estradiol patches releasing 50-100 μg/24 hours are preferred due to lower cardiovascular risk compared to oral formulations 1
Transdermal administration avoids first-pass hepatic metabolism, reducing thrombotic risk 1, 2
Vaginal gel (0.5-1 mg daily) is another option for estrogen delivery 1

Spironolactone is commonly used in the United States to suppress testosterone production 1
Target dose typically 100-300 mg daily, divided into once or twice daily dosing 1
Cyproterone acetate (not available in US) is effective but carries potential health risks 1

Measure trough testosterone levels with target <50 ng/dL (female range) 1
Monitor estradiol levels; traditional target range of 100-200 pg/mL, though recent evidence questions this specific range 1
Regular monitoring of liver function, lipid profile, and hemoglobin/hematocrit 1, 2

Increased risk of venous thromboembolism, especially with oral estrogen formulations 1, 2
Risk increases with age and is higher with ethinyl estradiol 2
Potential for unfavorable lipid profiles and increased cardiovascular mortality 2

Confirm gender dysphoria diagnosis and readiness for hormone therapy 1
Screen for contraindications (history of estrogen-sensitive cancers, uncontrolled cardiovascular disease) 1, 2
Begin transdermal 17β-estradiol patch (50 μg/24 hours) and start spironolactone 50-100 mg daily, divided into 1-2 doses 1
Check testosterone and estradiol levels after 1-3 months and adjust doses based on clinical response and laboratory values 1
Continue monitoring hormone levels every 3-6 months during first year, then annually 1
Annual physical examination and laboratory monitoring 1, 2

The American College of Physicians and other medical guidelines suggest that hormonal therapy is associated with improved mental health outcomes in transgender individuals, with systematic reviews showing a 20% decrease in depression after 1 year of treatment and no evidence of adverse mental health effects, according to high-quality evidence 3, 4
Transgender individuals have significantly elevated rates of anxiety, depression, and suicide attempts, with lack of access to hormone treatment being a specific risk factor for poor mental health outcomes, based on moderate-quality evidence 3, 4
The mental health benefits of initiating therapy likely outweigh the risks of delaying treatment while awaiting specialist consultation, according to low-quality evidence 4

Guidelines recommend combining transdermal estradiol with an antiandrogen such as spironolactone to achieve testosterone levels <50 ng/dL (female range), based on moderate-quality evidence 5

Baseline screening for cardiovascular risk factors should be considered given increased thrombotic risk, according to low-quality evidence 6

Transdermal 17β-estradiol is preferred over oral formulations because it avoids first-pass hepatic metabolism, significantly reducing thrombotic risk, based on high-quality evidence 6
Increased risk of venous thromboembolism, stroke, and myocardial infarction exists in trans women compared to cisgender women, with risk persisting despite modern lower-dose preparations, according to moderate-quality evidence 6
Applying heat sources (warming devices) over transdermal patches should be avoided as this increases absorption unpredictably, based on low-quality evidence 6

Physical changes develop gradually over 6-24 months, with breast development sustained over the first three years, according to moderate-quality evidence 5